| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $239,532 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Weiss Lawrence T | SVP, Chief Legal Officer | 1 | $118,100 | 0 | $0 | $118,100 |
| Clemmer James C | President and CEO | 1 | $111,500 | 0 | $0 | $111,500 |
| Trowbridge Stephen A | EVP and CFO | 1 | $9,932 | 0 | $0 | $9,932 |
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Over the last 12 months, insiders at AngioDynamics, Inc. have bought $239,532 and sold $0 worth of AngioDynamics, Inc. stock.
On average, over the past 5 years, insiders at AngioDynamics, Inc. have bought $277,357 and sold $706,907 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Weiss Lawrence T (SVP, Chief Legal Officer) — $118,100. Clemmer James C (President and CEO) — $111,500. Trowbridge Stephen A (EVP and CFO) — $9,932.
The last purchase of 10,000 shares for transaction amount of $118,100 was made by Weiss Lawrence T (SVP, Chief Legal Officer) on 2025‑10‑21.
| 2025-10-21 | Weiss Lawrence T | SVP, Chief Legal Officer | 10,000 0.0246% | $11.81 | $118,100 | +2.78% | ||
| 2025-10-13 | Trowbridge Stephen A | EVP and CFO | 890 0.0022% | $11.16 | $9,932 | +7.32% | ||
| 2025-10-09 | Clemmer James C | President and CEO | 10,000 0.0244% | $11.15 | $111,500 | +7.05% | ||
| 2025-01-16 | Sale | Nighan Warren JR | SVP Quality and Regulatory | 4,060 0.0096% | $12.31 | $49,979 | -19.03% | |
| 2024-10-10 | Nighan Warren JR | SVP Quality and Regulatory | 100 0.0002% | $6.08 | $608 | +53.26% | ||
| 2024-10-08 | Trowbridge Stephen A | EVP and CFO | 1,700 0.0033% | $5.86 | $9,962 | +59.95% | ||
| 2024-10-07 | Clemmer James C | President and CEO | 20,000 0.0399% | $6.03 | $120,600 | +54.10% | ||
| 2024-10-07 | Nighan Warren JR | SVP Quality and Regulatory | 768 0.0015% | $6.09 | $4,677 | +54.10% | ||
| 2024-04-08 | Clemmer James C | President and CEO | 10,000 0.0254% | $6.70 | $67,000 | +11.95% | ||
| 2023-01-31 | Sale | Helsel Dave | SVP Global Operations and R&D | 4,633 0.0117% | $12.95 | $59,997 | -34.26% | |
| 2022-10-12 | Trowbridge Stephen A | EVP and CFO | 1,083 0.0027% | $13.82 | $14,967 | -23.56% | ||
| 2022-10-10 | Clemmer James C | President and CEO | 10,000 0.0264% | $15.00 | $150,000 | -24.97% | ||
| 2022-07-29 | Sale | Helsel Dave | SVP Global Operations and R&D | 5,000 0.0126% | $22.44 | $112,200 | -43.39% | |
| 2022-04-28 | Sale | Helsel Dave | SVP Global Operations and R&D | 3,513 0.009% | $22.44 | $78,832 | -37.25% | |
| 2022-04-12 | Sale | JOHNSON WESLEY | director | 1,299 0.0034% | $23.26 | $30,215 | -34.97% | |
| 2022-04-11 | Sale | JOHNSON WESLEY | 7,500 0.0197% | $23.05 | $172,838 | -31.92% | ||
| 2022-01-12 | Trowbridge Stephen A | EVP and CFO | 2,000 0.0052% | $22.64 | $45,280 | -6.16% | ||
| 2022-01-11 | Clemmer James C | President and CEO | 20,000 0.0498% | $22.84 | $456,800 | -11.60% | ||
| 2021-10-20 | Sale | Helsel Dave | SVP Global Operations and R&D | 6,988 0.0176% | $27.97 | $195,454 | -21.70% | |
| 2021-10-15 | Sale | Centea Scott | Sr. VP/GM, Global VIT | 24,000 0.0627% | $27.92 | $670,080 | -18.23% |
| Clemmer James C | President and CEO | 882529 2.1412% | $9.94M | 9 | 0 | +19.36% |
| Trowbridge Stephen A | EVP and CFO | 256629 0.6226% | $2.89M | 5 | 2 | +38.44% |
| Weiss Lawrence T | SVP, Chief Legal Officer | 93597 0.2271% | $1.05M | 1 | 0 | |
| STERN HOWARD S | director, 10 percent owner | 1647687 3.9976% | $18.55M | 0 | 35 | |
| Burgstahler David F | 381406 0.9254% | $4.29M | 0 | 3 | ||
| Avista Capital Partners GP, LLC | 10 percent owner | 381406 0.9254% | $4.29M | 0 | 3 | |
| MEYERS DAVID P | director | 336980 0.8176% | $3.79M | 0 | 33 | |
| HOBBS EAMONN P | President & CEO | 100401 0.2436% | $1.13M | 3 | 27 | +11.44% |
| BUCCI VINCENT | director | 86696 0.2103% | $976,196.96 | 9 | 0 | <0.0001% |
| JOHNSON WESLEY | director | 79704 0.1934% | $897,467.04 | 2 | 3 | <0.0001% |
| Gould Kevin J | director | 55124 0.1337% | $620,696.24 | 3 | 1 | +8.54% |
| DONNELLY HOWARD W | director | 47600 0.1155% | $535,976.00 | 3 | 1 | +17.81% |
| Centea Scott | Sr. VP/GM, Global VIT | 46244 0.1122% | $520,707.44 | 0 | 1 | |
| Nighan Warren JR | SVP Quality and Regulatory | 41817 0.1015% | $470,859.42 | 2 | 1 | +53.68% |
| DEVIVO JOSEPH | President and CEO | 38000 0.0922% | $427,880.00 | 4 | 0 | <0.0001% |
| ECHENBERG PAUL S | Director Emeritus | 31976 0.0776% | $360,049.76 | 0 | 1 | |
| Campbell Chad Thomas | SVP/GM, Vascular Access | 31741 0.077% | $357,403.66 | 0 | 1 | |
| Kapusta Matthew C | SVP, Business Development | 27005 0.0655% | $304,076.30 | 2 | 0 | +8.01% |
| GOLD JEFFREY | director | 25233 0.0612% | $284,123.58 | 1 | 1 | +6.67% |
| Meteny Dennis S | director | 21950 0.0533% | $247,157.00 | 2 | 0 | +16.07% |
| Greiner Charles R | VP - Global Franchise | 20910 0.0507% | $235,446.60 | 0 | 5 | |
| Richard Stark | SVP, GM - Oncology | 20754 0.0504% | $233,690.04 | 0 | 4 | |
| Greiner Michael | EVP and CFO | 20731 0.0503% | $233,431.06 | 0 | 1 | |
| Helsel Dave | SVP Global Operations and R&D | 19189 0.0466% | $216,068.14 | 0 | 5 | |
| Keltjens Jan | President & CEO | 15000 0.0364% | $168,900.00 | 4 | 0 | +18.72% |
| LaPorte Steve | director | 8013 0.0194% | $90,226.38 | 8 | 0 | +1.5% |
| Shea Paul J | VP - Sales | 2562 0.0062% | $28,848.12 | 0 | 13 | |
| Orsatti Charles Thomas | director | 2000 0.0049% | $22,520.00 | 1 | 0 | +20% |
| FLAHERTY ROBERT E | director | 1200 0.0029% | $13,512.00 | 1 | 0 | +19.04% |
| ROSSELL ROBERT M | VP - Marketing | 1000 0.0024% | $11,260.00 | 1 | 7 | +116.9% |
| RECINELLA DANIEL | VP - Product Development | 892 0.0022% | $10,043.92 | 0 | 3 | |
| Stern Linda B | 10 percent owner | 891 0.0022% | $10,032.66 | 0 | 26 | |
| APPLING WILLIAM M | Vice-President - Research | 654 0.0016% | $7,364.04 | 0 | 17 | |
| Casciaro Gregory D | director | 500 0.0012% | $5,630.00 | 1 | 0 | +19.04% |
| REED JAN STERN | director | 316 0.0008% | $3,558.16 | 1 | 0 | +2.38% |
| GERARDI JOSEPH G | Vice President | 242 0.0006% | $2,724.92 | 0 | 25 | |
| KUNST BRIAN | VP - Regulatory Affairs | 0 0% | $0 | 0 | 6 | |
| MAPES HAROLD | VP - Operations | 0 0% | $0 | 0 | 12 |
| Increased Positions | 90 | +63.83% | 7M | +17.48% |
| Decreased Positions | 58 | -41.13% | 2M | -6.61% |
| New Positions | 31 | New | 2M | New |
| Sold Out Positions | 13 | Sold Out | 767,392 | Sold Out |
| Total Postitions | 173 | +22.7% | 42M | +10.87% |
| Divisadero Street Capital Management, Lp | $46,639.00 | 8.97% | 3.68M | +282,695 | +8.33% | 2025-09-30 |
| Blackrock, Inc. | $44,059.00 | 8.48% | 3.47M | -56,633 | -1.6% | 2025-09-30 |
| Systematic Financial Management Lp | $32,594.00 | 6.27% | 2.57M | +60,600 | +2.41% | 2025-09-30 |
| Point72 Asset Management, L.P. | $32,446.00 | 6.24% | 2.56M | +609,906 | +31.3% | 2025-09-30 |
| Vanguard Group Inc | $29,977.00 | 5.77% | 2.36M | -125,090 | -5.03% | 2025-09-30 |
| Millennium Management Llc | $22,737.00 | 4.37% | 1.79M | +393,682 | +28.13% | 2025-09-30 |
| Armistice Capital, Llc | $20,744.00 | 3.99% | 1.64M | +108,185 | +7.08% | 2025-09-30 |
| Segall Bryant & Hamill, Llc | $16,732.00 | 3.22% | 1.32M | -37,140 | -2.74% | 2025-09-30 |
| Bastion Asset Management Inc. | $16,028.00 | 3.08% | 1.26M | +304,960 | +31.8% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $14,654.00 | 2.82% | 1.16M | -16,916 | -1.44% | 2025-09-30 |